Fibronectin based scaffold domain proteins that bind to myostatin

US11813315B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Sharon Cload · Cambridge, US
• Linda Engle · Framingham, US
• Dasa Lipovsek · Pepperell, US
• Malavi Madireddi · Plainsboro, US
• Ginger Rakestraw · Cambridge, US
• Joanna Swain · Concord, US
• Wenjun ZHAO · Montgomery, US
• Hui Wei · Princeton Junction, US
• Aaron P. YAMNIUK · Lawrenceville, US
• Vidhyashankar Ramamurthy · Kanchinakote, IN
• Alexander T. Kozhich · Princeton, US
• Martin J. Corbett · Mount Holly, US
• Stanley Krystek · Ringoes, US

Key dates

• Filing date: Feb 14, 2019
• Grant date: Nov 14, 2023
• Expiry date: May 18, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/31
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.